Rallybio (NASDAQ:RLYB) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Rallybio from “hold” to “buy,” but Weiss Ratings maintained a “sell (D-)” rating; MarketBeat lists the stock’s overall average rating as “Sell.”
• Rallybio shares opened at $16.99, near their one-year high of $17.57, with a $90.22 million market capitalization. The company reported a quarterly loss of $1.09 per share, beating estimates for a $1.28 loss, but continued to post sharply negative profitability metrics.
• Institutional ownership is substantial at 90.34%, with several hedge funds increasing their positions. Rallybio is a clinical-stage biotechnology company developing treatments for rare genetic diseases, including its lead program RBX-100 for congenital athymia.

Rallybio (NASDAQ:RLYB - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Rallybio in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Rallybio currently has an average rating of "Sell".

Rallybio Price Performance

NASDAQ:RLYB opened at $16.99 on Friday. The firm has a market capitalization of $90.22 million, a P/E ratio of -3.91 and a beta of -0.90. Rallybio has a one year low of $3.67 and a one year high of $17.57. The company's 50-day simple moving average is $16.09 and its 200 day simple moving average is $11.80.

Rallybio (NASDAQ:RLYB - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($1.09) earnings per share for the quarter, beating analysts' consensus estimates of ($1.28) by $0.19. Rallybio had a negative net margin of 911.07% and a negative return on equity of 40.53%.

Insider Transactions at Rallybio

In other news, major shareholder Adar1 Capital Management, Llc bought 10,200 shares of the company's stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average price of $13.98 per share, for a total transaction of $142,596.00. Following the completion of the purchase, the insider owned 926,352 shares in the company, valued at approximately $12,950,400.96. This represents a 1.11% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 10.30% of the company's stock.

Hedge Funds Weigh In On Rallybio

Hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC boosted its stake in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock valued at $219,000 after purchasing an additional 373,821 shares during the last quarter. Susquehanna International Group LLP increased its holdings in shares of Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock worth $68,000 after purchasing an additional 113,031 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock worth $170,000 after purchasing an additional 2,996 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock worth $573,000 after purchasing an additional 120,892 shares during the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock valued at $67,000 after purchasing an additional 38,205 shares in the last quarter. 90.34% of the stock is currently owned by hedge funds and other institutional investors.

About Rallybio

Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source